Actively Recruiting

Phase 2
Age: 18Years - 85Years
FEMALE
Healthy Volunteers
NCT04831437

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

Led by Tehran University of Medical Sciences · Updated on 2021-10-12

60

Participants Needed

1

Research Sites

360 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.

CONDITIONS

Official Title

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

Who Can Participate

Age: 18Years - 85Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathology of squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of uterine cervix
  • International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, IIB, IIIA (with hydronephrosis but without creatinine clearance compromise), or IIIC1 (less than 3 lymph nodes under 3cm and no common iliac chain involvement)
  • Patient eligible for definitive chemoradiotherapy followed by brachytherapy
Not Eligible

You will not qualify if you...

  • Creatinine clearance less than 30 ml/min
  • Any histology other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • Need for paraaortic lymph node irradiation
  • Inflammatory bowel disease
  • Connective tissue disorders
  • Previous pelvic radiotherapy
  • FIGO stage IA or IV
  • Eastern Cooperative Oncology Group (ECOG) performance status above 2
  • History of previous hysterectomy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Imam Khomeini Hospital Complex

Tehran, Iran, 1419733141

Actively Recruiting

Loading map...

Research Team

K

Kasra Kolahdouzan, M.D.

CONTACT

E

Ebrahim Esmati, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer | DecenTrialz